Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022
Ashlan J Kunz Coyne,Sara Alosaimy,Kristen Lucas,Abdalhamid M Lagnf,Taylor Morrisette,Kyle C Molina,Alaina DeKerlegand,Melanie Rae Schrack,S Lena Kang-Birken,Athena L V Hobbs,Jazmin Agee,Nicholson B Perkins 3rd,Mark Biagi,Michael Pierce,James Truong,Justin Andrade,Jeannette Bouchard,Tristan Gore,Madeline A King,Benjamin M Pullinger,Kimberly C Claeys,Shelbye Herbin,Reese Cosimi,Serina Tart,Michael P Veve,Bruce M Jones,Leonor M Rojas,Amy K Feehan,Marco R Scipione,Jing J Zhao,Paige Witucki,Michael J Rybak
DOI: https://doi.org/10.1128/spectrum.02351-23
2024-01-11
Abstract:The rise of multidrug-resistant (MDR) pathogens, especially MDR Gram-negatives, poses a significant challenge to clinicians and public health. These resilient bacteria have rendered many traditional antibiotics ineffective, underscoring the urgency for innovative therapeutic solutions. Eravacycline, a broad-spectrum fluorocycline tetracycline antibiotic approved by the FDA in 2018, emerges as a promising candidate, exhibiting potential against a diverse array of MDR bacteria, including Gram-negative, Gram-positive, anaerobic strains, and Mycobacterium. However, comprehensive data on its real-world application remain scarce. This retrospective cohort study, one of the largest of its kind, delves into the utilization of eravacycline across various infectious conditions in the USA during its initial 4 years post-FDA approval. Through assessing clinical, microbiological, and tolerability outcomes, the research offers pivotal insights into eravacycline's efficacy in addressing the pressing global challenge of MDR bacterial infections.